Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Asset Writedowns and Impairment (2016 - 2024)

Theravance Biopharma (TBPH) has disclosed Asset Writedowns and Impairment for 4 consecutive years, with -$13000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Asset Writedowns and Impairment changed N/A to -$13000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $1.6 million, a N/A change, with the full-year FY2024 number at $4.5 million, changed N/A from a year prior.
  • Asset Writedowns and Impairment was -$13000.0 for Q4 2024 at Theravance Biopharma, down from $1.6 million in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $1.6 million in Q3 2024 to a low of -$13000.0 in Q4 2024.